By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported fourth-quarter revenue growth of 21 percent, driven by its forensic testing services in the UK and US.

The Princeton, NJ-based firm had total revenues of $15.7 million for the three-month period ended Dec. 31, compared to $13 million for the fourth quarter of 2008. Its service revenues rose to $14.9 million from $13 million year over year, led by forensic testing in the UK and US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.